Einloggen

Thematische Bibliographien / Drug Resistance / Zeitschriftenartikel

Um die anderen Arten von Veröffentlichungen zu diesem Thema anzuzeigen, folgen Sie diesem Link: Drug Resistance.

Zeitschriftenartikel zum Thema „Drug Resistance“

Autor: Grafiati

Veröffentlicht am 4. Juni 2021

Zuletzt aktualisiert am 2. November 2024

Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an

Wählen Sie eine Art der Quelle aus:

Machen Sie sich mit Top-50 Zeitschriftenartikel für die Forschung zum Thema "Drug Resistance" bekannt.

Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.

Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.

Sehen Sie die Zeitschriftenartikel für verschiedene Spezialgebieten durch und erstellen Sie Ihre Bibliographie auf korrekte Weise.

1

K, Tiwari. „Drug Resistance: Challenges and Updates“. Journal of Natural & Ayurvedic Medicine 3, Nr. 3 (15.07.2019): 1–2. http://dx.doi.org/10.23880/jonam-16000196.

Der volle Inhalt der Quelle

Annotation:

Use of antibiotics increased dramatically in last two decades. To cure most of the diseases broad spectrum antibiotics given. Human society and healthcare is going in wrong direction. One way the pharmaceutical companies are making huge money from it. The other way around is the overuse of these antibiotics, by patients knowing or unknowingly, not only making pathogens adapted but also the normal flora organisms becoming pathogens in coming future? Present article highlight the issues and possible solution of the present scenario.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

2

Singh, Amresh Kumar. „Resistance patterns and trends of extensively drug-resistant tuberculosis: 5-year experience“. Journal of Microbiology and Infectious Diseases 03, Nr. 04 (01.12.2013): 169–75. http://dx.doi.org/10.5799/ahinjs.02.2013.04.0103.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

3

Dyary, Hiewa Othman. „Veterinary Anthelmintics and Anthelmintic Drug Resistance“. Journal of Zankoy Sulaimani - Part A 18, Nr. 1 (12.11.2015): 191–206. http://dx.doi.org/10.17656/jzs.10463.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

4

Çelik, Cem. „Increasing antimicrobial resistance in nosocomial pathogens; multidrug-resistant extensively drug-resistant and pandrug-resistant Acinetobacter baumannii“. Journal of Microbiology and Infectious Diseases 4, Nr. 1 (01.03.2014): 7–12. http://dx.doi.org/10.5799/ahinjs.02.2014.01.0116.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

5

Giaccone, Giuseppe, und Herbert M. Pinedo. „Drug Resistance“. Oncologist 1, Nr. 1-2 (Februar 1996): 82–87. http://dx.doi.org/10.1634/theoncologist.1-1-82.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

6

Hochhauser, D., und A. L. Harris. „Drug resistance“. British Medical Bulletin 47, Nr. 1 (1991): 178–96. http://dx.doi.org/10.1093/oxfordjournals.bmb.a072454.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

7

Prichard, R. K. „Drug resistance“. International Journal for Parasitology 29, Nr. 1 (Januar 1999): 137–38. http://dx.doi.org/10.1016/s0020-7519(98)00191-x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

8

Texidó, Gemma, und Jürgen Moll. „Drug resistance“. Drug Discovery Today: Technologies 11 (März 2014): 1–3. http://dx.doi.org/10.1016/j.ddtec.2014.03.013.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

9

Köser, Claudio U., Babak Javid, Kathleen Liddell, Matthew J. Ellington, Silke Feuerriegel, Stefan Niemann, Nicholas M. Brown et al. „Drug-resistance mechanisms and tuberculosis drugs“. Lancet 385, Nr. 9965 (Januar 2015): 305–7. http://dx.doi.org/10.1016/s0140-6736(14)62450-8.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

10

Coen, Donald M., und Richard J. Whitley. „Antiviral drugs and antiviral drug resistance“. Current Opinion in Virology 1, Nr. 6 (Dezember 2011): 545–47. http://dx.doi.org/10.1016/j.coviro.2011.10.024.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

11

Hall, Andrew G., und Julie Irving. „New drugs, new drug resistance mechanisms“. Expert Review of Anticancer Therapy 2, Nr. 3 (Juni 2002): 239–340. http://dx.doi.org/10.1586/14737140.2.3.239.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

12

Kumar, Saurabh, und Richa Prasad Mahato. „DRUG RESISTANCE AND RESISTANCE REVERSAL STRATEGIES IN MALARIA PARASITE“. Journal of microbiology, biotechnology and food sciences 13, Nr. 5 (05.02.2024): e10384. http://dx.doi.org/10.55251/jmbfs.10384.

Der volle Inhalt der Quelle

Annotation:

The public health care system is currently facing a major problem with malaria. Globally, malarial deaths have decreased by an estimated 40% in the past two decades because of the clinically effective drugs (artemisinin-based combination therapies) against Plasmodium falciparum. In recent years, P falciparum develop resistance against all antimalarial drugs and then becomes developed multidrug resistance that a major challenge. Even though drug discovery programs have made substantial progress in the past decade, the potential for new drugs/combinations to improve the effectiveness of current malaria control strategies. Beyond, we have compiled a comprehensive review of clinically approved anti-malarial drugs with resistance mechanisms and a novel drug-resistance reversal approach in one place to meet this demand. The review aimed to provide detailed information on drug resistance, its regulatory molecular mechanisms responsible for resistance, and the novel available treatment of malaria. In this review, the article will help in developing effective interventions, potential approaches, and strategies to handle antimalarial resistance. This will prevent life-threatening infections.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

13

Yusuf, Yenni. „ANTI-MALARIAL DRUG RESISTANCE“. Majalah Kedokteran Andalas 37, Nr. 1 (03.05.2015): 64. http://dx.doi.org/10.22338/mka.v37.i1.p64-69.2014.

Der volle Inhalt der Quelle

Annotation:

AbstrakTujuan studi ini adalah untuk menjelaskan mekanisme resistensi parasit malaria danusaha-usaha yang dapat dilakukan untuk menghadapi munculnya strain parasit yangresisten terhadap artemisinin. Metode yang digunakan adalah studi kepustakaan. ResistensiP.falciparum terhadap obat-obat anti malaria disebabkan oleh perubahan spontan yangterjadi pada beberapa gen seperti P.falciparum multi drug resistance1 (Pfmdr1), P.falciparumchloroquine transporter (Pfcrt), P.falciparum dihydropteroate synthase (Pfdhps), P.falciparumdihydrofolate reductase (Pfdhfr), and P.falciparum multidrug resistance-associated proteins(Pfmrp). Penyebaran resistensi tersebut dipengaruhi oleh tingkat transmisi di sebuah wilayah.WHO telah menjalankan usaha untuk menanggulangi penyebaran resistensi tersebut misalnyadengan merekomendasikan penghentian monoterapi artemisinin, dan pemberian anti malariasetelah konfirmasi laboratorium. Selain itu, perlu adanya penggunaan obat kombinasi, produksirejimen dosis tetap, dan pengembangan obat anti malaria baru. Kesimpulan dari hasil studiini ialah munculnya malaria resisten terhadap artemisinin akan menghambat usaha eradikasimalaria karena itu diperlukan usaha-usaha untuk menanggulanginya.AbstractThe objective of this study was to describe the development of anti-malarial drug resistanceof the parasites and the efforts taken to contain the emergence of artemisinin resistant malaria.This was a literature study. The development of resistance to anti-malarial drugs are due tospontaneous changes in certain genes such as of P.falciparum multi drug resistance1 (Pfmdr1),P.falciparum chloroquine resistance transporter (Pfcrt), P.falciparum dihydropteroate synthase(Pfdhps), P.falciparum dihydrofolate reductase (Pfdhfr), and P.falciparum multidrug resistanceassociatedproteins (Pfmrp). The spread of the resistance depends on the transmission ratewithin each area. WHO has established a global plan to contain the spread of this resistance,such as recommendation to withdraw artemisinin-based monotherapies and administrationof treatment after laboratory confirmation. In addition, administration of anti-malarial drugcombination, production of fixed dose regimen and development of new drugs are necessary.The Conclusion is emergence of artemisinin resistant malaria will threaten malaria eradicationthus some efforts are necessarily needed to contain it.Afiliasi penulis: Bagian Parasitologi Fakultas Kedokteran Universitas Hasanudin

APA, Harvard, Vancouver, ISO und andere Zitierweisen

14

Nyce, J., S. Leonard, D. Canupp, S. Schulz und S. Wong. „Epigenetic mechanisms of drug resistance: drug-induced DNA hypermethylation and drug resistance.“ Proceedings of the National Academy of Sciences 90, Nr. 7 (01.04.1993): 2960–64. http://dx.doi.org/10.1073/pnas.90.7.2960.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

15

Hossain, Chowdhury Mobaswar, Lisa Kathleen Ryan, Meeta Gera, Sabyasachi Choudhuri, Nazmun Lyle, Kazi Asraf Ali und Gill Diamond. „Antifungals and Drug Resistance“. Encyclopedia 2, Nr. 4 (10.10.2022): 1722–37. http://dx.doi.org/10.3390/encyclopedia2040118.

Der volle Inhalt der Quelle

Annotation:

Antifungal drugs prevent topical or invasive fungal infections (mycoses) either by stopping growth of fungi (termed fungistatic) or by killing the fungal cells (termed fungicidal). Antibiotics also prevent bacterial infections through either bacteriostatic or bactericidal mechanisms. These microorganisms successfully develop resistance against conventional drugs that are designed to kill or stop them from multiplying. When a fungus no longer responds to antifungal drug treatments and continues to grow, this is known as antifungal drug resistance. Bacteria have an amazing capacity to become resistant to antibiotic action as well, and the effectiveness of the scarce antifungal arsenal is jeopardised by this antibiotic resistance, which poses a severe threat to public health.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

16

Perfect, John R., und Gary M. Cox. „Drug resistance in Cryptococcus neoformans“. Drug Resistance Updates 2, Nr. 4 (August 1999): 259–69. http://dx.doi.org/10.1054/drup.1999.0090.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

17

Kennedy, David A., und Andrew F. Read. „Why does drug resistance readily evolve but vaccine resistance does not?“ Proceedings of the Royal Society B: Biological Sciences 284, Nr. 1851 (29.03.2017): 20162562. http://dx.doi.org/10.1098/rspb.2016.2562.

Der volle Inhalt der Quelle

Annotation:

Why is drug resistance common and vaccine resistance rare? Drugs and vaccines both impose substantial pressure on pathogen populations to evolve resistance and indeed, drug resistance typically emerges soon after the introduction of a drug. But vaccine resistance has only rarely emerged. Using well-established principles of population genetics and evolutionary ecology, we argue that two key differences between vaccines and drugs explain why vaccines have so far proved more robust against evolution than drugs. First, vaccines tend to work prophylactically while drugs tend to work therapeutically. Second, vaccines tend to induce immune responses against multiple targets on a pathogen while drugs tend to target very few. Consequently, pathogen populations generate less variation for vaccine resistance than they do for drug resistance, and selection has fewer opportunities to act on that variation. When vaccine resistance has evolved, these generalities have been violated. With careful forethought, it may be possible to identify vaccines at risk of failure even before they are introduced.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

18

Croft, Simon L., Shyam Sundar und Alan H. Fairlamb. „Drug Resistance in Leishmaniasis“. Clinical Microbiology Reviews 19, Nr. 1 (Januar 2006): 111–26. http://dx.doi.org/10.1128/cmr.19.1.111-126.2006.

Der volle Inhalt der Quelle

Annotation:

SUMMARY Leishmaniasis is a complex disease, with visceral and cutaneous manifestations, and is caused by over 15 different species of the protozoan parasite genus Leishmania. There are significant differences in the sensitivity of these species both to the standard drugs, for example, pentavalent antimonials and miltefosine, and those on clinical trial, for example, paromomycin. Over 60% of patients with visceral leishmaniasis in Bihar State, India, do not respond to treatment with pentavalent antimonials. This is now considered to be due to acquired resistance. Although this class of drugs has been used for over 60 years for leishmaniasis treatment, it is only in the past 2 years that the mechanisms of action and resistance have been identified, related to drug metabolism, thiol metabolism, and drug efflux. With the introduction of new therapies, including miltefosine in 2002 and paromomycin in 2005-2006, it is essential that there be a strategy to prevent the emergence of resistance to new drugs; combination therapy, monitoring of therapy, and improved diagnostics could play an essential role in this strategy.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

19

de Koning, Harry P. „Drug resistance in protozoan parasites“. Emerging Topics in Life Sciences 1, Nr. 6 (22.12.2017): 627–32. http://dx.doi.org/10.1042/etls20170113.

Der volle Inhalt der Quelle

Annotation:

As with all other anti-infectives (antibiotics, anti-viral drugs, and anthelminthics), the limited arsenal of anti-protozoal drugs is being depleted by a combination of two factors: increasing drug resistance and the failure to replace old and often shamefully inadequate drugs, including those compromised by (cross)-resistance, through the development of new anti-parasitics. Both factors are equally to blame: a leaking bathtub may have plenty of water if the tap is left open; if not, it will soon be empty. Here, I will reflect on the factors that contribute to the drug resistance emergency that is unfolding around us, specifically resistance in protozoan parasites.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

20

Kurt Yilmaz, Nese, und Celia A. Schiffer. „Introduction: Drug Resistance“. Chemical Reviews 121, Nr. 6 (24.03.2021): 3235–37. http://dx.doi.org/10.1021/acs.chemrev.1c00118.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

21

Emery, VC. „Cytomegalovirus Drug Resistance“. Antiviral Therapy 3, Nr. 4 (Mai 1998): 239–42. http://dx.doi.org/10.1177/135965359800300403.

Der volle Inhalt der Quelle

Annotation:

Clinical resistance of cytomegalovirus (CMV) against the currently licensed antiviral drugs is becoming an increasingly recognized problem. This review focuses on the molecular basis of resistance and describes mutations in the UL54 DNA polymerase leading to resistance against cidofovir, foscarnet and ganciclovir. The review highlights two important developments in our appreciation of resistance. Firstly, the use of more rapid molecular based assays to detect genotypic resistance and secondly, the relationship between resistance profiles in multiple organ systems of the same host. Finally, the changing face of CMV disease in the era of highly active antiviral chemotherapy is considered with respect to its impact on the frequency of CMV resistance in the clinic.

APA, Harvard, Vancouver, ISO und andere Zitierweisen

22

Clavel, François, und Allan J. Hance. „HIV Drug Resistance“. New England Journal of Medicine 350, Nr. 10 (04.03.2004): 1023–35. http://dx.doi.org/10.1056/nejmra025195.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

23

Richman, D. D. „HIV Drug Resistance“. Annual Review of Pharmacology and Toxicology 33, Nr. 1 (April 1993): 149–64. http://dx.doi.org/10.1146/annurev.pa.33.040193.001053.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

24

Davies, Peter, und Damian Cullen. „Antituberculosis drug resistance“. Clinical Medicine 9, Nr. 1 (01.02.2009): 91.1–91. http://dx.doi.org/10.7861/clinmedicine.9-1-91.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

25

Perrin, Luc. „Drug resistance mutations“. AIDS 18, Nr. 8 (Mai 2004): 1201–2. http://dx.doi.org/10.1097/00002030-200405210-00014.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

26

White, Nicholas J. „Antimalarial drug resistance“. Journal of Clinical Investigation 113, Nr. 8 (15.04.2004): 1084–92. http://dx.doi.org/10.1172/jci21682.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

27

Tesio, Melania. „Starving Drug Resistance“. HemaSphere 4, Nr. 6 (10.11.2020): e495. http://dx.doi.org/10.1097/hs9.0000000000000495.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

28

Pizzorno, Andrés, Yacine Abed und Guy Boivin. „Influenza Drug Resistance“. Seminars in Respiratory and Critical Care Medicine 32, Nr. 04 (August 2011): 409–22. http://dx.doi.org/10.1055/s-0031-1283281.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

29

COEN, DONALD M. „Antiviral Drug Resistance“. Annals of the New York Academy of Sciences 616, Nr. 1 AIDS (Dezember 1990): 224–36. http://dx.doi.org/10.1111/j.1749-6632.1990.tb17843.x.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

30

Weitzman, Jonathan B. „Cancer drug resistance“. Genome Biology 2 (2001): spotlight—20010626–01. http://dx.doi.org/10.1186/gb-spotlight-20010626-01.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

31

Flintoff, Wayne F. „Acquired drug resistance“. Genome 31, Nr. 1 (01.01.1989): 447. http://dx.doi.org/10.1139/g89-073.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

32

Gold, Howard S., und Robert C. Moellering. „Antimicrobial-Drug Resistance“. New England Journal of Medicine 335, Nr. 19 (07.11.1996): 1445–53. http://dx.doi.org/10.1056/nejm199611073351907.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

33

Phelps, Charles E. „Bug/Drug Resistance“. Medical Care 27, Nr. 2 (Februar 1989): 194–203. http://dx.doi.org/10.1097/00005650-198902000-00009.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

34

Robertson, John D. „CANCER DRUG RESISTANCE“. Shock 26, Nr. 6 (Dezember 2006): 638. http://dx.doi.org/10.1097/01.shk.0000248599.09507.90.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

35

RICHMAN, DOUGLAS D. „HIV Drug Resistance“. AIDS Research and Human Retroviruses 8, Nr. 6 (Juni 1992): 1065–71. http://dx.doi.org/10.1089/aid.1992.8.1065.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

36

Schmit, Jean-Claude. „HIV drug resistance“. HIV Clinical Trials 3, Nr. 3 (Mai 2002): 225–26. http://dx.doi.org/10.1310/kmkn-ke48-2gwu-g0he.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

37

Richman, Douglas D. „Viral drug resistance“. Current Opinion in Infectious Diseases 3, Nr. 6 (Dezember 1990): 819–23. http://dx.doi.org/10.1097/00001432-199012000-00014.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

38

Loeffler, Juergen, und David A. Stevens. „Antifungal Drug Resistance“. Clinical Infectious Diseases 36, Supplement_1 (15.01.2003): S31—S41. http://dx.doi.org/10.1086/344658.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

39

Richman, Douglas D. „Antiviral drug resistance“. Antiviral Research 71, Nr. 2-3 (September 2006): 117–21. http://dx.doi.org/10.1016/j.antiviral.2006.03.004.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

40

Calmy, Alexandra, Fernando Pascual und Nathan Ford. „HIV Drug Resistance“. New England Journal of Medicine 350, Nr. 26 (24.06.2004): 2720–21. http://dx.doi.org/10.1056/nejm200406243502621.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

41

Pillay, D., und A. M. Geddes. „Antiviral drug resistance“. BMJ 313, Nr. 7056 (31.08.1996): 503–4. http://dx.doi.org/10.1136/bmj.313.7056.503.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

42

Richman, Douglas D. „Antiretroviral drug resistance“. AIDS 5, Supplement (Januar 1991): 189. http://dx.doi.org/10.1097/00002030-199101001-00027.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

43

Richman, Douglas D. „HIV DRUG RESISTANCE“. AIDS 8, Supplement 4 (November 1994): S3. http://dx.doi.org/10.1097/00002030-199411004-00010.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

44

STEVENSON, AUDREY M. „Emerging Drug Resistance“. MCN, The American Journal of Maternal/Child Nursing 23, Nr. 4 (Juli 1998): 216. http://dx.doi.org/10.1097/00005721-199807000-00010.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

45

Pillay, D., und M. Zambon. „Antiviral drug resistance“. BMJ 317, Nr. 7159 (05.09.1998): 660–62. http://dx.doi.org/10.1136/bmj.317.7159.660.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

46

Field, Hugh J., und Siân E. Goldthorpe. „Antiviral drug resistance“. Trends in Pharmacological Sciences 10, Nr. 8 (August 1989): 333–37. http://dx.doi.org/10.1016/0165-6147(89)90069-2.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

47

Dannenberg, Jan-Hermen, und Anton Berns. „Drugging Drug Resistance“. Cell 141, Nr. 1 (April 2010): 18–20. http://dx.doi.org/10.1016/j.cell.2010.03.020.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

48

Hampton, Tracy. „Cancer Drug Resistance“. JAMA 309, Nr. 1 (02.01.2013): 20. http://dx.doi.org/10.1001/jama.2012.173440.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

49

McCloskey, William W. „Microbial Drug Resistance“. JAMA: The Journal of the American Medical Association 278, Nr. 6 (13.08.1997): 523. http://dx.doi.org/10.1001/jama.1997.03550060099047.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

50

Hampton, Tracy. „Melanoma Drug Resistance“. JAMA 296, Nr. 4 (26.07.2006): 384. http://dx.doi.org/10.1001/jama.296.4.384-b.

Der volle Inhalt der Quelle

APA, Harvard, Vancouver, ISO und andere Zitierweisen

Wir bieten Rabatte auf alle Premium-Pläne für Autoren, deren Werke in thematische Literatursammlungen aufgenommen wurden. Kontaktieren Sie uns, um einen einzigartigen Promo-Code zu erhalten!